Latest News and Press Releases

MORRISVILLE, N.C., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023....

Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation...

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ labelLitigation is tied to same ‘793 patent previously...

MORRISVILLE, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023. The...

MORRISVILLE, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023....

No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for...

Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPRFederal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024If PTAB...

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizerLiquidia funds $10 million...

MORRISVILLE, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs, Chief Executive Officer, and Mr. Michael Kaseta, Chief...

MORRISVILLE, N.C., May 19, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced the Company will present data related to the investigational use...